

Seeking Non-invasive and/or Personalized Delivery Systems for Complex Therapies

The Impulse by Chiesi, the Open Innovation team within the global research-oriented biopharmaceutical group, is launching a call for opportunities focused on novel drug delivery systems to enhance drug targeting and patient outcomes. Through Inpart Connect, the team seeks innovative solutions in three defined areas of interest.

Oral delivery of biologics - oral administration of peptides, proteins or more complex biotherapeutics to support home-based care, improve adherence and simplify treatment. Approaches should address enzymatic degradation and poor intestinal absorption, which restrict the feasibility of oral delivery. Novel formulations, devices, or enabling technologies are within scope.

Non-Invasive delivery to bypass the blood-brain-barrier - enhance therapeutic outcomes and patient experience, by enabling non-invasive drug delivery routes (e.g. intranasal) that bypass the blood-brain barrier. Solutions that improve targeting efficiency, bioavailability, and ease of use, whether through novel formulations, devices, or biological mechanisms.

Personalized and customizable delivery systems for ultra-precise dosing - delivery systems to tailor dosing for individual needs, which is critical in areas like paediatrics, geriatrics and rare diseases. Any solution that allows flexible, on-demand production of personalized dosage forms, with priority given to modular, scalable platforms. Strategies to enable doses to be adapted based on patient-specific characteristics such as age, weight, disease progression, or monitored clinical indicators (e.g., biomarkers, organ function), enabling dynamic and responsive treatment strategies.

- **Oral, lung, nasal, parenteral intranasal, and other non-invasive approaches are in scope.**
- **Developmental Stages of Interest:** Solutions with TRL 3-6 are of high interest. Submissions should have a minimum of *in vitro* validation, with a preference for *in vivo* data or first in-human studies.
- **Out of Scope:** Diagnostic approaches or methods, analytical technologies, oral delivery of small molecules. Submissions from individual physicians or others working in hospital/private practice.

Submission Information: Submissions should include a one-page summary (200–300-words) along with any supplementary information such as relevant publications or patents. Applicants are strongly encouraged to include a slide-deck (or similar presentation) outlining their solution and plans to bring it to market for patient benefit. Chiesi welcomes submissions from all applicants, including early-stage researchers, using this [submission form](#) to describe their research and proposed next steps.

The Impulse by Chiesi is open to a range of collaboration models, including support for small proof-of-concept or pilot studies to validate solutions that align with its needs. Details regarding intellectual property and licensing will be discussed on a case-by-case basis. By submitting to this campaign, you confirm that your submission contains only non-confidential information.



Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies
-  Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **7th January 2026 - 11:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk